Obesity Drug Market Boom: Three Stocks Poised for Growth
The obesity drug sector has emerged as one of healthcare's most explosive growth opportunities, with sales projected to skyrocket from $15 billion in 2023 to $150 billion by 2035. Current-generation injectable therapies dominate, but oral formulations nearing approval could reshape the competitive landscape.
Eli Lilly (LLY) leads the U.S. market with its tirzeptatide-based drugs Mounjaro and Zepbound, boasting 1.1 million active prescriptions. The company's rapid market share gains come as competitors face manufacturing challenges. Lilly's pipeline includes orforglipron, a once-daily oral GLP-1 medication that could further solidify its position.